阿哌沙班 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "阿哌沙班" in Chinese language version.

refsWebsite

Global rank Chinese rank

29web.archive.org

1^st place

8nih.gov

4^th place

5^th place

7fda.gov

447^th place

581^st place

5doi.org

2^nd place

23^rd place

2drugs.com

399^th place

208^th place

2europa.eu

68^th place

209^th place

2pfizer.com

low place

7,863^rd place

2clincalc.com

3,912^th place

5,917^th place

1medicines.org.uk

3,823^rd place

3,456^th place

1books.google.com

3^rd place

8^th place

1handle.net

102^nd place

492^nd place

1biospace.com

low place

1nice.org.uk

3,258^th place

2,433^rd place

1semanticscholar.org

11^th place

332^nd place

1medpagetoday.com

9,274^th place

low place

1medicaldialogues.in

low place

1jdsupra.com

low place

1biopharmadive.com

low place

5,099^th place

1natlawreview.com

9,177^th place

low place

1drugstorenews.com

low place

1apotex.com

low place

1fiercepharma.com

low place

apotex.com

First Generic Alternative to Eliquis Now Available in Canada. Apotex (新闻稿). 2022-07-20 [2023-06-29]. （原始内容存档于2024-01-18）.

biopharmadive.com

Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug. BioPharma Dive. [2021-11-30]. （原始内容存档于2023-12-28）.

biospace.com

With Court Win, BMS and Pfizer Stave Off Generic Challengers to Eliquis – For Now. BioSpace. [2021-11-29]. （原始内容存档于2023-04-02）.

books.google.com

Kiser K. Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. 2017: 11. ISBN 9783319546438.

clincalc.com

The Top 300 of 2020. ClinCalc. [2022-10-07]. （原始内容存档于2021-02-12）.
Apixaban - Drug Usage Statistics. ClinCalc. [2022-10-07]. （原始内容存档于2020-02-28）.

doi.org

Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis. 2013, 2013: 640723. PMC 3885278 . PMID 24455237. doi:10.1155/2013/640723 .
Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. Annals of Internal Medicine. December 2018, 169 (11): 774–787. PMC 6825839 . PMID 30383133. doi:10.7326/M18-1523.
Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. British Journal of Clinical Pharmacology. February 2013, 75 (2): 476–487. PMC 3558798 . PMID 22759198. doi:10.1111/j.1365-2125.2012.04369.x.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. September 2011, 365 (11): 981–992. PMID 21870978. S2CID 43262809. doi:10.1056/NEJMoa1107039 .
Cada DJ, Levien TL, Baker DE. Apixaban. Hospital Pharmacy. June 2013, 48 (6): 494–509. PMC 3839491 . PMID 24421512. doi:10.1310/hpj4806-494.

drugs.com

Apixaban (Eliquis) Use During Pregnancy. Drugs.com. 2019-06-21 [2020-08-13]. （原始内容存档于2021-04-14）.
Apixaban Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [2019-03-27]. （原始内容存档于2019-03-27）.

drugstorenews.com

Levy S. Apotex offers generic Eliquis in Canada. Drugstore News. 2022-08-01 [2022-09-02]. （原始内容存档于2023-09-25）.

europa.eu

ema.europa.eu

Eliquis EPAR. European Medicines Agency. 2018-09-17 [2020-04-22]. （原始内容存档于2020-08-11）. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
No change is needed in use of direct oral anticoagulants following EMA-funded study. European Medicines Agency (EMA). 2020-03-27 [2020-04-22]. （原始内容存档于2020-04-22）.

fda.gov

FDA approves first generics of Eliquis. U.S. Food and Drug Administration (FDA). 2019-12-23 [2019-12-23]. （原始内容存档于2019-12-23）. 本文含有此來源中屬於公有领域的内容。
Atrial fibrillation and new oral anticoagulant drugs. U.S. Food and Drug Administration (FDA). 2015-12-02 [2020-04-22]. （原始内容存档于2020-04-22）.
Atrial fibrillation, oral anticoagulant drugs, and their reversal agents. U.S. Food and Drug Administration. 2015-12-02 [2020-04-22]. （原始内容存档于2020-04-22）.
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). U.S. Food and Drug Administration (FDA). 2018-12-31 [2020-04-22]. （原始内容存档于2020-05-29）.
2019 First Generic Drugs Approvals. U.S. Food and Drug Administration (FDA). t 2020-08-05 [2023-06-30]. （原始内容存档于2023-06-30）. 请检查|date=中的日期值 (帮助)

accessdata.fda.gov

Drug Approval Package: Eliquis (apixaban) NDA #202155. U.S. Food and Drug Administration (FDA). 2013-2-13 [2019-12-23]. （原始内容存档于2019-12-23）. 请检查|date=中的日期值 (帮助)
FDA-Approved Drugs: Eliquis (apixaban). U.S. Food and Drug Administration (FDA). [2019-12-23]. （原始内容存档于2020-09-30）.

fiercepharma.com

Kansteiner, Fraiser. Drugs from J&J, Merck, Novartis, BMS and more set for first round of Medicare price negotiations: CMS. 2023-08-29 [2023-08-31]. （原始内容存档于2024-04-03）.

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533 . WHO/MHP/HPS/EML/2021.02.

jdsupra.com

Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc.. JD Supra. [2021-11-30]. （原始内容存档于2023-04-02）.

medicaldialogues.in

business.medicaldialogues.in

FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis. Business Medical Dialogues (New Delhi, India: Minerva Medical Treatment). 2019-12-24 [2019-12-24]. （原始内容存档于2019-12-25）.

medicines.org.uk

Eliquis 5 mg film-coated tablets - Summary of Product Characteristics (SmPC). (emc). 2022-05-03 [2022-10-08]. （原始内容存档于2024-02-22）.

medpagetoday.com

Neale T. FDA OKs Apixaban for DVT Prevention. MedPage Today. 2014-03-14 [2015-09-17]. （原始内容存档于2015-09-07）.

natlawreview.com

Federal Circuit Crystallizes BMS' Apixaban District Court Win. The National Law Review. [2021-11-30]. （原始内容存档于2023-04-02）.

nice.org.uk

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (PDF). National Institute for Health and Care Excellence. January 2013 [2016-02-26]. （原始内容存档于2016-03-05）.

nih.gov

ncbi.nlm.nih.gov

Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis. 2013, 2013: 640723. PMC 3885278 . PMID 24455237. doi:10.1155/2013/640723 .
Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. Annals of Internal Medicine. December 2018, 169 (11): 774–787. PMC 6825839 . PMID 30383133. doi:10.7326/M18-1523.
Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. British Journal of Clinical Pharmacology. February 2013, 75 (2): 476–487. PMC 3558798 . PMID 22759198. doi:10.1111/j.1365-2125.2012.04369.x.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. September 2011, 365 (11): 981–992. PMID 21870978. S2CID 43262809. doi:10.1056/NEJMoa1107039 .
Cada DJ, Levien TL, Baker DE. Apixaban. Hospital Pharmacy. June 2013, 48 (6): 494–509. PMC 3839491 . PMID 24421512. doi:10.1310/hpj4806-494.

dailymed.nlm.nih.gov

Eliquis- apixaban tablet, film coated Eliquis 30-day starter pack- apixaban kit. DailyMed. 2019-11-26 [2020-04-22]. （原始内容存档于2021-03-07）.
Andexxa- andexanet alfa injection, powder, lyophilized, for solution. DailyMed. 2019-01-08 [2019-12-23]. （原始内容存档于2020-11-18）.

pubchem.ncbi.nlm.nih.gov

Apixaban. PubChem, US National Library of Medicine. 2022-08-27 [2022-09-02]. （原始内容存档于2020-01-03）.

pfizer.com

Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds. Pfizer (新闻稿). [2021-12-25]. （原始内容存档于2015-09-10）.
U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy (新闻稿). Pfizer. 2014-08-21 [2016-02-26]. （原始内容存档于2014-10-23）.

semanticscholar.org

api.semanticscholar.org

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. September 2011, 365 (11): 981–992. PMID 21870978. S2CID 43262809. doi:10.1056/NEJMoa1107039 .

web.archive.org

Apixaban (Eliquis) Use During Pregnancy. Drugs.com. 2019-06-21 [2020-08-13]. （原始内容存档于2021-04-14）.
Eliquis 5 mg film-coated tablets - Summary of Product Characteristics (SmPC). (emc). 2022-05-03 [2022-10-08]. （原始内容存档于2024-02-22）.
Eliquis- apixaban tablet, film coated Eliquis 30-day starter pack- apixaban kit. DailyMed. 2019-11-26 [2020-04-22]. （原始内容存档于2021-03-07）.
Eliquis EPAR. European Medicines Agency. 2018-09-17 [2020-04-22]. （原始内容存档于2020-08-11）. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Apixaban Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [2019-03-27]. （原始内容存档于2019-03-27）.
FDA approves first generics of Eliquis. U.S. Food and Drug Administration (FDA). 2019-12-23 [2019-12-23]. （原始内容存档于2019-12-23）. 本文含有此來源中屬於公有领域的内容。
Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds. Pfizer (新闻稿). [2021-12-25]. （原始内容存档于2015-09-10）.
Drug Approval Package: Eliquis (apixaban) NDA #202155. U.S. Food and Drug Administration (FDA). 2013-2-13 [2019-12-23]. （原始内容存档于2019-12-23）. 请检查|date=中的日期值 (帮助)
The Top 300 of 2020. ClinCalc. [2022-10-07]. （原始内容存档于2021-02-12）.
Apixaban - Drug Usage Statistics. ClinCalc. [2022-10-07]. （原始内容存档于2020-02-28）.
With Court Win, BMS and Pfizer Stave Off Generic Challengers to Eliquis – For Now. BioSpace. [2021-11-29]. （原始内容存档于2023-04-02）.
Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (PDF). National Institute for Health and Care Excellence. January 2013 [2016-02-26]. （原始内容存档于2016-03-05）.
Atrial fibrillation and new oral anticoagulant drugs. U.S. Food and Drug Administration (FDA). 2015-12-02 [2020-04-22]. （原始内容存档于2020-04-22）.
Atrial fibrillation, oral anticoagulant drugs, and their reversal agents. U.S. Food and Drug Administration. 2015-12-02 [2020-04-22]. （原始内容存档于2020-04-22）.
No change is needed in use of direct oral anticoagulants following EMA-funded study. European Medicines Agency (EMA). 2020-03-27 [2020-04-22]. （原始内容存档于2020-04-22）.
Andexxa- andexanet alfa injection, powder, lyophilized, for solution. DailyMed. 2019-01-08 [2019-12-23]. （原始内容存档于2020-11-18）.
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). U.S. Food and Drug Administration (FDA). 2018-12-31 [2020-04-22]. （原始内容存档于2020-05-29）.
FDA-Approved Drugs: Eliquis (apixaban). U.S. Food and Drug Administration (FDA). [2019-12-23]. （原始内容存档于2020-09-30）.
Neale T. FDA OKs Apixaban for DVT Prevention. MedPage Today. 2014-03-14 [2015-09-17]. （原始内容存档于2015-09-07）.
U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy (新闻稿). Pfizer. 2014-08-21 [2016-02-26]. （原始内容存档于2014-10-23）.
Apixaban. PubChem, US National Library of Medicine. 2022-08-27 [2022-09-02]. （原始内容存档于2020-01-03）.
FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis. Business Medical Dialogues (New Delhi, India: Minerva Medical Treatment). 2019-12-24 [2019-12-24]. （原始内容存档于2019-12-25）.
2019 First Generic Drugs Approvals. U.S. Food and Drug Administration (FDA). t 2020-08-05 [2023-06-30]. （原始内容存档于2023-06-30）. 请检查|date=中的日期值 (帮助)
Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc.. JD Supra. [2021-11-30]. （原始内容存档于2023-04-02）.
Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug. BioPharma Dive. [2021-11-30]. （原始内容存档于2023-12-28）.
Federal Circuit Crystallizes BMS' Apixaban District Court Win. The National Law Review. [2021-11-30]. （原始内容存档于2023-04-02）.
Levy S. Apotex offers generic Eliquis in Canada. Drugstore News. 2022-08-01 [2022-09-02]. （原始内容存档于2023-09-25）.
First Generic Alternative to Eliquis Now Available in Canada. Apotex (新闻稿). 2022-07-20 [2023-06-29]. （原始内容存档于2024-01-18）.
Kansteiner, Fraiser. Drugs from J&J, Merck, Novartis, BMS and more set for first round of Medicare price negotiations: CMS. 2023-08-29 [2023-08-31]. （原始内容存档于2024-04-03）.